Functional T cells from iPSCs Using Chimeric Antigen Receptors
Functional T cells from iPSCs Using Chimeric Antigen Receptors
批准号:
9760329
负责人:
Dar Heinze
金额:
$6.77万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2021-05-31
关键词:
Acute Lymphocytic LeukemiaAdultAffinityAntigensAreaAutoimmune ProcessBiological AssayBypassCD19 geneCD34 geneCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCRISPR/Cas technologyCell Differentiation processCell LineCell LineageCell MaturationCell TherapyCellsClinicalCuesCytotoxic T-LymphocytesDataDefectDerivation procedureDevelopmentDoxycyclineEndothelial CellsEndotheliumFellowshipFutureGoalsHaplotypesHematopoietic stem cellsImmunotherapyMalignant NeoplasmsMature T-LymphocyteMediatingMediator of activation proteinMedicineMethodsModificationMolecular ProfilingMusNatureNotch Signaling PathwayOutputPatientsPhasePopulationProductionProtocols documentationPublishingRegulatory T-LymphocyteReportingSignal PathwaySignal TransductionSomatic CellSpecificityStem cellsSurfaceT cell differentiationT-Cell DevelopmentT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireTechnologyTetanus Helper PeptideTetracyclinesTherapeuticTimeTransfusionTransplant RecipientsTumor stageUmbilical Cord BloodWorkbasechimeric antigen receptorchimeric antigen receptor T cellsdosageengineered T cellshematopoietic differentiationimprovedinduced pluripotent stem cellnext generationnovelprogenitorpromoterreceptorreceptor expressionsingle cell sequencingstem-like cellsuccesstranscriptome sequencing
中文摘要
项目总结:
英文摘要
Project Summary:
T cell immunotherapy is poised to be a major player in the future of medicine. The success of CD19 CAR T
cells in acute lymphoblastic leukemia has been impressive and gives a glimpse of what the next generation of
engineered T cells may be capable of. In the future, CAR-targeted T cells may be valuable immunotherapy for
more than just cancer. In particular, targeted T regulatory cell therapy is a promising possibility for treatment of
autoimmune conditions and tolerance induction in transplant recipients. Current methods of CAR T cell
production are dependent on laborious isolation, modification, and expansion steps on a per-patient basis.
This makes them highly expensive with little possibility of an off-the-shelf product. Induced pluripotent stem
cells (iPSC) allow the reprogramming of adult somatic cells to a stem-cell like fate from patients with specific
MHC haplotypes to overcome this issue. The combination of MHC-banked iPSCs and CAR technology sets
the stage for a renewable and highly controllable off-the-shelf T cell therapeutic. However, efforts to
differentiate iPSCs into T cells have struggled with the production of hematopoietic progenitors with robust T
cell potential and a blockade in T cell maturation at the CD4/8 double positive stage. In this proposal we
demonstrate the marked impact of modulating the NOTCH signaling pathway on T-capable progenitor output.
We propose to combine this success with single-cell RNAseq to reveal the true identity of the T cell progenitor.
This work will uncover key signaling pathways and answer lingering questions about the nature of iPSC-
derived hematopoietic progenitors. It will also leverage improved efficiency in differentiation cultures. In
addition, we propose to use temporally controlled expression of CARs with a range of antigen affinities during
T cell differentiation to bypass their developmental blockade and drive maturation into functional T cells.
These two synergistic but not dependent goals will be a vital and powerful step toward truly functional iPSC-
derived T cells and would also open the door for exploring signals necessary to drive CD4 helper T cell
commitment and T reg lineage specification.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金